We are live on
!
Find out more
Axa Portfolio holdings
AUM
$91.9M
1-Year Est. Return
27.41%
This Fund
S&P 500
This Quarter
Est. Return
+5.26%
1 Year Est. Return
+27.41%
3 Year Est. Return
+100.68%
5 Year Est. Return
+129.89%
10 Year Est. Return
+554.73%
AUM
$24B
AUM Growth
+$1.05B
(+4.6%)
Cap. Flow
-$221M
Cap. Flow
% of AUM
-0.92%
Top 10 Holdings %
Top 10 Hldgs %
13.73%
Holding
1,494
New
103
Increased
612
Reduced
406
Closed
115
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$114M |
| 2 |
AET
Aetna Inc
AET
|
+$96.3M |
| 3 |
Travelers Companies
TRV
|
+$94.5M |
| 4 |
CHK
Chesapeake Energy Corporation
CHK
|
+$89M |
| 5 |
Ameren
AEE
|
+$69.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Deutsche Bank
DB
|
+$247M |
| 2 |
Verizon
VZ
|
+$186M |
| 3 |
Medtronic
MDT
|
+$150M |
| 4 |
LO
LORILLARD INC COM STK
LO
|
+$126M |
| 5 |
Johnson Controls International
JCI
|
+$104M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.44% |
| 2 | Technology | 14.68% |
| 3 | Financials | 12.75% |
| 4 | Industrials | 11.1% |
| 5 | Energy | 9.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
iShares Expanded Tech Sector ETF
IGM
$10.6B
| $35.6M | 0.15% |
2,243,700
+333,000
| +17% | +$5.07M |
|
177
Marvell Technology
MRVL
$197B
| $35.2M | 0.15% |
2,459,800
+137,500
| +6% | +$2.12M |
|
178
Avnet
AVT
$7.58B
| $35.2M | 0.15% |
795,474
-160,310
| -17% | -$7.05M |
|
179
Huntsman Corp
HUN
$1.63B
| $35.2M | 0.15% |
1,250,926
-1,301
| -0.1% | -$34.1K |
|
180
AbbVie
ABBV
$463B
| $35M | 0.15% |
620,125
+96,816
| +19% | +$5.08M |
|
181
US Bancorp
USB
$97.7B
| $34.6M | 0.14% |
799,098
-27,924
| -3% | -$1.17M |
|
182
Altria Group
MO
$118B
| $34.3M | 0.14% |
818,158
+34,629
| +4% | +$1.39M |
|
183
NiSource
NI
$19.7B
| $34.1M | 0.14% |
2,204,700
+627,161
| +40% | +$9.07M |
|
184
Vertex Pharmaceuticals
VRTX
$132B
| $33.9M | 0.14% |
358,355
+116,167
| +48% | +$8.15M |
|
185
Televisa
TV
$1.25B
| $33.3M | 0.14% |
970,132
+196,411
| +25% | +$6.59M |
|
186
Rockwell Automation
ROK
$46.5B
| $32.9M | 0.14% |
262,605
-16,610
| -6% | -$2.05M |
|
187
Brown-Forman Class B
BF.B
$12B
| $32.7M | 0.14% |
1,083,806
+1,027,556
| +1,827% | +$30.1M |
|
188
Illumina
ILMN
$31.4B
| $32.4M | 0.13% |
186,353
-23,991
| -11% | -$3.58M |
|
|
LO
189
DELISTED
LORILLARD INC COM STK
LO
| $32.1M | 0.13% |
526,164
-2,169,889
| -80% | -$126M |
|
190
Vanguard FTSE Developed Markets ETF
VEA
$234B
| $30.6M | 0.13% |
717,900
-27,900
| -4% | -$1.18M |
|
191
iShares Morningstar Mid-Cap Value ETF
IMCV
$1.17B
| $30.2M | 0.13% |
728,211
+38,400
| +6% | +$1.53M |
|
192
Bausch Health
BHC
$2.21B
| $30.1M | 0.13% |
237,765
-51,413
| -18% | -$6.56M |
|
193
Mondelez International
MDLZ
$79.6B
| $29.8M | 0.12% |
792,421
+135,186
| +21% | +$4.94M |
|
194
Helmerich & Payne
HP
$4.26B
| $29.8M | 0.12% |
256,359
+75,770
| +42% | +$8.3M |
|
195
LyondellBasell Industries
LYB
$20.3B
| $28.8M | 0.12% |
294,876
+41,739
| +16% | +$3.97M |
|
196
Westlake Corp
WLK
$8.81B
| $28.7M | 0.12% |
342,200
-5,200
| -1% | -$389K |
|
|
RAD
197
DELISTED
Rite Aid Corporation
RAD
| $28.4M | 0.12% |
+197,700
| New | +$29.2M |
|
198
Bristol-Myers Squibb
BMY
$131B
| $28.3M | 0.12% |
583,513
+22,133
| +4% | +$1.09M |
|
|
MJN
199
DELISTED
Mead Johnson Nutrition Company
MJN
| $28.2M | 0.12% |
302,644
+7,777
| +3% | +$680K |
|
200
Cummins
CMI
$74.5B
| $28.1M | 0.12% |
182,369
+22,699
| +14% | +$3.43M |
|
Similar funds
VI
FA
PBCM
CCAM
GBA
AWP
HI
DCA
Axa's Q2 2014 Portfolio in Review
As of Q2 2014, Axa held 1,494 positions worth $24B, up 4.6% from $23B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Axa's Q2 2014 filing shows 103 new, 612 increased, 406 reduced and 115 closed positions. Its largest new stake was Boston Scientific: 4,394,250 shares worth $56.1M. The largest sale was Deutsche Bank, an estimated $247M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 16% a quarter earlier, followed by Technology and Financials.
- Axa's largest Q2 2014 buy was Boston Scientific: 4,394,250 shares worth $56.1M.
- Axa added most to Gilead Sciences in Q2 2014, an estimated $114M increase.
- Axa's biggest Q2 2014 reduction was Deutsche Bank, cutting an estimated $247M.
- Axa fully exited OMNICARE INC in Q2 2014, selling an estimated $20.4M.
- Axa's ten largest holdings make up 14% of its $24B portfolio in Q2 2014.
- Axa opened 103 new positions and closed 115 in Q2 2014.
- Axa's portfolio value rose 4.6% quarter-over-quarter to $24B.
Based on Axa's 13F filing for Q2 2014, filed 13 Aug 2014.